Form 4: BridgeBio Pharma CFO Awarded Restricted Stock Units

BridgeBio Pharma's CFO, Brian C. Stephenson, received 42,683 restricted stock units (RSUs) that vest over two years.

Summary

• Brian C. Stephenson, the Secretary, Treasurer, and CFO of BridgeBio Pharma, Inc., was granted 42,683 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of the company's common stock for each unit.
• Half of the RSUs will vest on December 12, 2025, and the remaining half will vest on December 12, 2026.
• Vesting is contingent upon Mr. Stephenson's continued service with BridgeBio Pharma or its subsidiaries through each vesting date.
• The RSUs have no expiration date.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It is a positive but not exceptional event.

Positives

• The grant of RSUs aligns the CFO's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Risks

• The value of the RSUs is dependent on the future stock price of BridgeBio Pharma.
• If Mr. Stephenson leaves the company before the vesting dates, he may forfeit the unvested RSUs.

Industry Context

Equity compensation, such as RSUs, is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• RSU grants are a standard form of compensation for executives in the biotech industry, often vesting over a period of 2-4 years.
• The vesting schedule of 1/2 in 1 year and the remaining 1/2 in 2 years is a fairly standard vesting schedule for RSU grants.

Stakeholder Impact

• Shareholders may view this as a positive sign of management alignment with company performance.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

Restricted Stock Units, RSUs, BridgeBio Pharma, Brian C. Stephenson, CFO, Stock Options, Equity Compensation, Vesting